Klaus leads clinical development of the Inhibrx pipeline. Prior to joining Inhibrx, Klaus trained as a fellow of the M.D. Anderson Cancer Center. He then worked as a medical oncologist at the Banner M.D. Anderson Cancer Center, where he also served as the local principal investigator for clinical trials of cancer immunotherapy agents. Klaus’s scientific work at Genentech and the Genomics Institute of the Novartis Research Foundation (GNF) focused on drug discovery and predictive biomarker development. Klaus received the highest academic honors and was a Scholar of the German Merit Foundation. He received his M.D. and Ph.D. from the Friedrich-Alexander University of Erlangen in Germany.